CFDA approves Gilead propien sand ® for treatment of adult strains with chronic hepatitis C virus 1-6

Gilead ScientificCompany(NASDAQ: GILD) announced that the NationalDrug(the Supervisory Authority approved the propane sand ® (Sophobuvir 400 mg / Vipatavir 100 mg) can be used to treat adult strains of chronic hepatitis C virus (HCV) with the gene 1-6the State Drug Administration also approved the use of cat-sand ® combined ribavirin (RBV) for adult patients with hepatitis C during the combined replacement period of cirrhosisprotosconosis ® is the first ugenous HCV single tablet program (STR) approved in Chinaclenbutechon sand ® is approved in China, based on five international multicenter Phase 3 clinical studies, namely ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 and ASTRAL-5In a hard-to-cure group of patients (including treated patients, as well as patients with trified or indemnity cirrhosis), SVR12 (defined as the 12th week after completion of treatment) had a higher overall achievement rate of 92%-100% of thedetection(not HCV RNA)in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 first-treatment and treated patients with type 1-6 HCV infection without cirrhosis/associated period of cirrhosis received 12 weeks of propane ® treatment98% (1,015/1,035) of patients achieved SVR12In the ASTRAL-5 study, 106 first-treatment and treatable patients with type 1-6 HCV infection with non-cured cirrhosis/associated cirrhosis received 12 weeks of propane ® treatment, as well as HIV infection and were receiving stable antiretroviral treatmentOf these, 95% (101/106) of patients achieved SVR12The ASTRAL-4 study assessed the safety and efficacy of 267 patients with gene 1-4 and Genotype 6 HCV infections who received 12-week propane-®/non-joint ribavirin (RBV) treatment or 24-week propane ® therapyOf these, 94% (82/87) of SVR12 was achieved in patients with out-of-paid cirrhosis treated with 12 weeks of propane ® combined with RBV adverse reactions
the most common adverse reactions (-10%) of patients treated with propane-sand ® in ASTRAL-1, ASTRAL-2, and ASTRAL-5 include headaches and fatigue In the ASTRAL-1 study, patients in the placebo group experienced similar frequency of headaches and fatigue In ASTRAL-4, the most common adverse reactions after treatment with propane salin ® and ribavirin (RBV) included fatigue, anemia, nausea, headache, insomnia, and diarrhea in patients with renuncitruary cirrhosis Four patients taking cactus ® combined WITH RBV were discontinued due to adverse reactions